Apyx Medical (NASDAQ:APYX) Announces Quarterly Earnings Results, Misses Expectations by $0.02 EPS
Apyx Medical (NASDAQ:APYX – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02), MarketWatch Earnings reports. Apyx Medical had a negative return on equity of 26.79% and a negative net margin of 31.27%. During the same period in the previous year, the company earned ($0.14) earnings per share. Apyx Medical updated its FY 2022 guidance to EPS.
APYX opened at $3.65 on Friday. The business has a 50-day moving average of $5.76 and a 200-day moving average of $10.14. Apyx Medical has a fifty-two week low of $3.01 and a fifty-two week high of $17.50.
Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in shares of Apyx Medical by 5.8% in the 1st quarter. Renaissance Technologies LLC now owns 512,006 shares of the company’s stock valued at $3,343,000 after acquiring an additional 28,211 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Apyx Medical by 16.1% in the 1st quarter. Rhumbline Advisers now owns 27,228 shares of the company’s stock valued at $178,000 after acquiring an additional 3,769 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Apyx Medical by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 18,314 shares of the company’s stock valued at $120,000 after acquiring an additional 6,649 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Apyx Medical by 2.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 302,606 shares of the company’s stock valued at $1,976,000 after acquiring an additional 6,150 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Apyx Medical by 0.8% in the 4th quarter. BlackRock Inc. now owns 1,990,093 shares of the company’s stock valued at $25,513,000 after acquiring an additional 15,857 shares in the last quarter. 61.03% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Apyx Medical from a “hold” rating to a “sell” rating in a research note on Friday. Piper Sandler cut their price target on Apyx Medical from $12.00 to $6.00 in a research note on Thursday. Finally, Colliers Securities reaffirmed a “buy” rating on shares of Apyx Medical in a research note on Tuesday, March 22nd.
About Apyx Medical (Get Rating)
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.
- Get a free copy of the StockNews.com research report on Apyx Medical (APYX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded